Disc Medicine (IRON) Stock News
$IRON · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Disc Medicine (IRON) in the past 30 days, 1 of it high impact. BORSA’s news read on IRON is bullish at 81/100, based on 1 company event over the past 7 days. IRON last closed at $56.84 on Oct 16, down 8.41% over five sessions and down 17.84% over the past month. Disc Medicine’s next earnings report is scheduled for Thursday, Nov 5.
The wire on $IRON
newest first · updated · direct subject stories onlyDisc Medicine: phase 3 APOLLO trial of bitopertin met all endpoints in EPP; plans NDA resubmission by end of 2026
Disc Medicine (IRON) reported that its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints. The company plans to resubmit an NDA by end of 2026 with an FDA decision expected by mid-2027. The stock was halted pending the announcement.
bullish 90 · impact 80